Luteal Phase Support With Daily Administration of Gonadotropin-releasing Hormone Agonist Compared to Progesterone/Estradiol in IVF/ICSI Cycles With Ovulation Triggering With GnRH-a
NCT ID: NCT05143723
Last Updated: 2021-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
102 participants
INTERVENTIONAL
2020-01-20
2022-06-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Materials and Methods: This prospective, controlled, randomized study, conducted at the Clinic of the Federal State Budgetary Educational Institution of Higher Education of the KubSMU of the Ministry of Health of Russia, included 102 patients at risk of developing ovarian hyperstimulation syndrome, who were on protocols with gonadotropin-releasing hormone antagonists and changing the ovulation trigger to a gonadotropin-releasing hormone agonist. All patients underwent blastocyst transfer on day 5. Patients of the first group (n = 51) received as support for the luteal phase gonadotropin-releasing hormone agonist daily 0.2 mg, subdermally, patients of the second group (n = 51) progesterone 10 mg 3 times a day, orally and estradiol 1 mg 3 times a day, transdermal. The level of progesterone on the day of transfer, the incidence of clinical pregnancy, and the incidence of ovarian hyperstimulation syndrome in both groups were compared.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Exclusion criteria: presence of external genital endometriosis; male factor of infertility; hydrosalpinx and/or tubo-ovarian formation (on one or both sides) according to hysterosalpingography and/or ultrasound investigation; malformations of internal genital organs, including conditions after surgical correction of malformations of internal genital organs; acquired deformities of the uterine cavity, in which embryo implantation or pregnancy is impossible; contraindications to the IVF/ICSI program; severe systemic diseases; cycles with cryopreserved sperm or oocytes; oocyte donation. The patients were divided into two groups using the envelope method. On days 2-5 of the menstrual cycle, a study of the level of blood hormones was carried out: follicle-stimulating hormone (FSH), luteinizing hormone (LH), progesterone, and estradiol, as well as transvaginal ultrasonography of the pelvic organs to determine the number of antral follicles (AFC) and exclusion of contraindications for the start of COS. Then СOS was carried out using gonadotropins, menotropins. The standard daily starting dose of stimulant drugs was determined according to age, BMI, original FSH, AFC, and ovarian response in women undergoing previous IVF/ICSI cycles. The ovarian response was assessed using folliculometry, starting from 5-6 days of COS, when two follicles with an average diameter of more than 14 mm or one more than 16 mm were reached, GnRH-ant was prescribed at a dose of 0.25 mg daily. Ovulation trigger (GnRH-a) was introduced on condition that two or more follicles with a diameter of 17-18 mm were reached; after 36 hours, transvaginal ovarian puncture (TVOP) was performed under ultrasound control. All mature eggs (ova) were fertilized using IVF or ICSI methods. Fertilization was assessed after about 20 hours, and the embryos were transferred into the uterine cavity on day 3 or 5. LPS in all patients started the day after oocyte retrieval and continued until 8 weeks of gestation in case of positive result.
Patients of the first group (n=51) received GNRH-a for LPS at a dose of 0.2 mg, subdermally, daily from the second day after TVOP. The second group of patients (n=51) received progesterone as LPS at a dosage of 30 mg per day, per os, and estradiol at a dosage of 3 mg per day, transdermally starting from the second day after TVOP till 8 weeks of pregnancy. The embryo transfer was carried out 3-5 days after TVOP, one or two embryos were transferred, depending on the morphological assessment of the embryo. On the day of transfer, a study of the level of progesterone in the peripheral blood was carried out. Pregnancy testing was performed by determining the level of β-hCG in the peripheral blood 14 days after the embryo transfer. Data were collected on participant characteristics, COS, and embryology. Characteristics included: patient's age, characteristics of ovarian reserve (AMH, FSH), type, duration and cause of infertility, duration of COS, the total dose of gonadotropin treatment, endometrial thickness on the day of ovulation trigger administration, number of oocytes and embryos retrieved. The outcomes were positive dynamics of β-hCG growth and clinical indicators of pregnancy. Clinical pregnancy was defined as an ongoing pregnancy with ultrasound imaging of the ovum and fetal heart rate.
Statistical analysis of data was carried out using STATISCA 10 package (Tibco, USA). Spearman's rank correlation coefficient, Mann-Whitney U test, Pearson's Chi-square test, Maximum likelihood Chi-square tests were used. p \<0.05 was considered statistically significant.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
agonist group
Patients of the first group received GNRH-a for LPS at a dose of 0.2 mg, subdermally, daily from the second day after TVOP till 8 weeks of pregnancy.
Gonadotropin-releasing hormone agonist
luteal phase support with gonadotropin-releasing hormone agonist
group of progesterone and estradiol
The second group of patients received progesterone as LPS at a dosage of 30 mg per day, per os, and estradiol at a dosage of 3 mg per day, transdermally starting from the second day after TVOP till 8 weeks of pregnancy
Gonadotropin-releasing hormone agonist
luteal phase support with gonadotropin-releasing hormone agonist
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gonadotropin-releasing hormone agonist
luteal phase support with gonadotropin-releasing hormone agonist
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Number of antral follicles (AFC) - more than 15 (menstrual cycle days 1-5)
* Stimulation of ovarian function in the protocol with GnRH-ant in IVF/ICSI cycles, with the change of the ovulation trigger to GnRH-a
* Tubal, unspecified and anovulatory infertility
* Body mass index (BMI) from 18 to 29 (inclusive)
* 15 or more follicles per day of ovulation trigger injection
Exclusion Criteria
* Male factor of infertility
* Hydrosalpinx and/or tubo-ovarian formation (on one or both sides) according to hysterosalpingography and/or ultrasound investigation
* Malformations of internal genital organs, including conditions after surgical correction of malformations of internal genital organs
* Acquired deformities of the uterine cavity, in which embryo implantation or pregnancy is impossible
* Contraindications to the IVF/ICSI program; severe systemic diseases
* Cycles with GnRH antagonists
20 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kuban State Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alisa Baklakova
doctor gynecologist
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alisa Baklakova
Krasnodar, Krasnodarskiy Kray, Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
04081990
Identifier Type: -
Identifier Source: org_study_id